Loading
LM-302 is an experimental antibody-drug conjugate from LaNova Medicines Zhejiang in phase 3 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2.
LM-302 is an antibody-drug conjugate developed by LaNova Medicines Zhejiang and Shanghai Chia Tai Tianqing Pharmaceutical Technology Development. Its target is Claudin 18.2 (the sponsor names CLDN18.2 (Claudin 18.2)). The sponsor states: LM-302 is an antibody-drug conjugate targeting CLDN18.2, evaluated in combination with tislelizumab versus tislelizumab plus chemotherapy in previously untreated, CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma. ClinicalTrials.gov describes the intervention as: The LM-302 injection is an ADC drug targeting CLDN18.2. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07385703 (Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma), in gastric & gastro-oesophageal junction cancer. The largest, NCT07385703, plans to enrol 752 participants with primary completion expected 2028-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
LM-302 is an antibody-drug conjugate targeting CLDN18.2, evaluated in combination with tislelizumab versus tislelizumab plus chemotherapy in previously untreated, CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma. Connects to Claudin 18.2.
1.LM-302's antibody arm binds Claudin 18.2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"LM-302" OR ABSTRACT:"LM-302") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LM-302, not a curated reading list.
Shares Claudin 18.2-positive gastric cancer, Claudin 18.2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.